Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Rituximab

Progressive multifocal leukoencephalopathy: 2 case reports

    • 9 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      RITUXIMAB (marketed as Rituxan): progressive multifocal leukoencephalopathy (PML). FDA Drug Safety Newsletter 1: 3-5, No. 1, 2007 - USA

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Rituximab. React. Wkly. 1175, 21 (2007). https://doi.org/10.2165/00128415-200711750-00073

    Download citation

    Keywords

    • Multiple Sclerosis
    • Doxorubicin
    • Vincristine
    • Progressive Multifocal Leukoencephalopathy
    • Occipital Lobe